An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3; Phase 2

Conditions: Obesity and Obesity-related Medical Conditions

Treatments: Drug: taranabant

Study type: Interventional

Funder types: Industry

Identifiers

NCT00131430

2005_044

0364-020

MK-0364-020

Details and patient eligibility

About

A study to determine the safety and efficacy of an investigational drug in patients with obesity.

Enrollment: 500 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Obese patients with a body mass index between 30kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43kg/m2, inclusive for those with obesity-related comorbidities including hypertension, dyslipidemia and sleep apnea).

Exclusion criteria

• Patients with serious or unstable current or past medical conditions.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind